Table 2

Details of subjects affected by thromboembolism in the follow-up period

Patient no.Age, ySexIg isotype (G or M)Time lag,* yPrimary prophylaxisType of event
113FemaleG5.4ASAStroke
261MaleG0.9Stroke
324FemaleG18.4ASARenal thrombotic microangiopathy
456FemaleG2.5Proximal DVT
554MaleG4ASAProximal DVT
625FemaleG1.8Stroke
743FemaleG1.5Proximal DVT
830FemaleG2.6PE
933FemaleG2Stroke
1054MaleG4Stroke
1122MaleM1.2Proximal DVT + PE
1257FemaleG2.1Myocardial infarction
1348MaleG2.4Stroke
1444FemaleG3.1Proximal DVT + PE
1538MaleG1.8Proximal DVT
1650MaleG1Proximal DVT + PE
1740MaleG3PE
1865FemaleG9TIA
1922FemaleG1.7Right atrial thrombosis
2057FemaleG5ASATIA
2141FemaleM11.5ASARetinal artery thrombosis
2255FemaleG4.8Proximal DVT
2345FemaleM2ASAProximal DVT
2453FemaleG3.2ASAStroke
2531FemaleG2.8Stroke
  • — indicates no primary prophylaxis; ASA, aspirin 100 mg 4 times a day; DVT, deep vein thrombosis; PE, pulmonary embolism; and TIA, transient ischemic attack.

  • * Time interval from laboratory finding to the thromboembolic event.

  • All the clinical events had a pertinent area of ischemia at cerebral imaging.